3SBio stock

1530 · HKEX · HKD

Compare 3SBio
$12.71Change from previous close: −3.64%Absolute change: −$0.48

Close · November 20, 2026

Price history

−60.77% over the period

1 year: from $32.40 (November 20, 2025) to $12.71 (November 20, 2026), −60.77%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$12.71
October 30, 2026$13.54
September 30, 2026$16.57
August 31, 2026$16.12
July 31, 2026$16.72
June 30, 2026$16.89
May 29, 2026$18.50
April 30, 2026$23.14
March 31, 2026$22.64
February 27, 2026$21.94
January 30, 2026$23.30
December 31, 2025$24.26
November 28, 2025$31.26
November 20, 2025$32.40

At a glance

  • The company

    Develops, produces and sells biopharmaceutical products for treating conditions including thrombocytopenia, anemia, rheumatoid arthritis, and cancer in China and internationally

  • Latest results

    Quarter to June 30, 2026 · EPS ¥0.44

TickerLandia's take on 3SBio

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$13.05
52-wk high$34.22

−62.86% from the 52-week high

Analysts · 14 analysts

Average target$28.90+127.40% vs. price

Buy 13 · Hold 1 · Sell 0 · Strong buy

TickerLandia Fingerprint: 3SBio

Compared with similar companies: very low price, very high profitability, and very weak momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

3SBio is cheaper than similar companies

3SBio's P/E (trailing 12 months): 3.90, −91% against the median of a group of 7 similar companies (44.1).

Compared with 7 similar companies

3SBio's metrics compared with similar companies
Metric3SBioPosition in the groupBand
P/E (trailing 12 months)3.90Low
Forward P/E10.6Low
Operating margin60.3%High
ROE35.9%High
Debt/equity0.05Middle

Grey band: the middle half of the group; tick: the median; dot: 3SBio. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥4.53B

Latest quarter · Q2 2026

Net income

¥1.15B

Latest quarter · Q2 2026

Quarterly net margin

25.3%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$35.76B
P/E
3.9
EPS
$3.70
Volume
11.42M
Daily trading
€26.61M
Dividend yield
1.97%
Last ex-dividend on July 21, 2026

How 3SBio is changing

All results
  • Revenue grew 25.9% a year on average over the last 5 years

  • Operating margin rose from 27.9% to 59.3%

  • Profits turn into cash: free cash flow equal to 109% of net income

Returns

3SBio returns with dividends

$1,000 invested in 3SBio 5 years ago, on November 22, 2021, would be worth $2,047 today with dividends reinvested: +104.72% in total, +15.43% per year. On price alone it would be $1,845 (+84.47%).

Period3SBioHang Seng$1,000 becomes
1 month−13.54%−6.10%$865
6 months−34.08%−12.63%$659
Year to date−47.61%−12.56%$524
1 year−60.19%−13.26%$398
3 years+89.99%+26.06%$1,900
5 years+104.72%−10.18%$2,047
10 years+55.00%+0.24%$1,550

Over the last 6 months it has done better than 7% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. Hang Seng: price only. Calculate your investment

The chart in detail

3SBio: technical analysis

3SBio is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 64.6% below its all-time closing high ($35.90, September 9, 2025).

Trend
Downward
RSI (14 sessions)
30
Between 30 and 70
vs 200-session average
−31.55%

Active signals

  • New 52-week low.

    since November 19, 2026

  • Close below the low of the previous 55 sessions.

Support and resistance

Price areas where 3SBio has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$16.18+27.30%2 touches, last on August 21, 2026
  2. Resistance$15.56+22.40%4 touches, last on November 6, 2026
  3. Resistance$14.97+17.78%3 touches, last on October 21, 2026
  4. Last price$12.71
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved more than the Hang Seng.

Beta (1 year) vs Hang Seng
1.26
Volatility (60 sessions, annualised)
45.5%
Largest fall in the last year
−60.77%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

3SBio: seasonality

Average monthly price change over 12 years

−0.7%Jan+0.1%Feb+11.3%Mar−1.1%Apr+8.1%May+2.1%Jun−4.0%Jul−1.6%Aug+2.8%Sep−3.2%Oct+6.0%Nov−4.4%Dec

Over the last 12 years, the strongest month for 3SBio has been March: +11.32% on average, positive in 9 years out of 11. The weakest has been December: −4.45% on average, positive in 5 years out of 11. November, the current month, has been positive in 8 years out of 11 (+5.99% on average).

Show chart data
MonthAverageMedianPositive years
January−0.66%−0.82%5 of 11
February+0.06%−0.92%5 of 11
March+11.32%+3.23%9 of 11
April−1.11%0.00%5 of 11
May+8.09%+4.24%7 of 11
June+2.09%+5.01%7 of 11
July−4.00%−4.82%1 of 12
August−1.59%−3.49%4 of 12
September+2.75%+2.84%8 of 12
October−3.20%−3.73%5 of 12
November+5.99%+4.31%8 of 11
December−4.45%−2.55%5 of 11

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

3SBio and its competitors

TPIAO, EPIAO, Yisaipu, Cipterbin and Mandi are the names people most associate with 3SBio Inc. Its biopharmaceutical portfolio addresses low platelet counts, anemia linked to chronic kidney disease, rheumatoid arthritis, psoriasis, breast cancer and hair loss. Beyond drug development and production, the group sells pharmaceuticals, operates pharmaceutical retail, and provides clinic, technology, agricultural and consulting services. Its activities reach the Chinese market, the United States and other countries.

Headquarters
Shenyang, China
Employees
6,068
Founded
1993
Chief executive
Jing Lou
3SBio and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
3SBio1530$4.56B60.3%3.90−34.08%
Akeso9926$6.81B-30.7%—−50.70%
Telix PharmaceuticalsTLX$2.92B6.2%92.3−7.71%
InSilico Medicine Cayman TopCo3696$2.59B-6.9%—−36.46%
Genscript Biotech1548$8.77B14.9%—+112.07%
Haisco Pharmaceutical Group002653$8.97B21.1%44.1+0.54%

Same industry or related industries, similar size. Compare 3SBio with its competitors · Full profile